Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Ensysce Biosciences Inc
ENSC
Alternate Symbol(s):
ENSCW
Healthcare
Biotechnology
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology...
, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ENSC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(83)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 06, 2024 11:15pm
Ensysce Biosciences Selected to Present at American Associat
JUST IN: $ENSC Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference~ PF614-MPAR recognized as potential medical breakthrough ~ SAN DIEGO, CA / ACCESSWIRE
...more
(83)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 31, 2024 11:00am
(NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting
Breaking News: $ENSC (NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting2024-01-31 09:03:48 ET DENVER, Colo., Jan. 31, 2023 ( www.247marketnews.com )- Ensysce Biosciences, Inc. (NASDAQ: ENSC)
...more
C.RVV Announces Type C Meeting Request Granted by FDA for Clinical Study
posted Apr 24, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA ...read more
(83)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 23, 2024 10:00am
Ensysce Biosciences Announces FDA Breakthrough Therapy Desig
Just In: $ENSC Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~ SAN
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 07, 2023 9:56am
New Press Release - Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website
SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. The...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 06, 2023 8:05am
New Press Release - Ensysce Biosciences to Participate in Upcoming Industry Events
Chief Medical Officer, Dr. William Schmidt, to Present at the CPDD 85th Annual Scientific MeetingChief Commercial Officer, Geoff Birkett, to Present Opening Address at EPHMRA 2023 Annual ConferenceSAN DIEGO, CA / ACCESSWIRE / June 6, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 15, 2023 4:30pm
New Press Release - Ensysce Biosciences Reports First Quarter 2023 Financial Results
Recently Completed Successful Ground-Breaking Study on Overdose Protection Recently Completed $7 Million Public OfferingSAN DIEGO, CA / ACCESSWIRE / May 15, 2023 /Ensysce Biosciences, Inc. ("Ensysce" or the "Company")(NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 12, 2023 4:40pm
New Press Release - Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc.(NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on May 10, 2023 8:58am
ENSC.... I have to give kudos to ENSC
I found this Co played by the rules and they were transparent enough to be able to pick spots to enter and exit. Most Co's are the complete opposite Cheers and Good Luck to ENSC !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 10, 2023 8:03am
New Press Release - Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / May 10, 2023 / Ensysce Biosciences, Inc.(NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today announced the pricing of a public offering of an...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on May 09, 2023 12:57pm
ENSC....filed yesterday...Check it out!
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716947/000149315223015752
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on May 09, 2023 9:38am
ENSC..... Great way to start off the morning ; )
That's a big F'king Cha Ching Sold all into the strength...... I feel confident this will go even higher ...past $7..... Remember...they will want to raise money I bet this will be a double
...more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on May 09, 2023 9:10am
ENSC.... Seems to me that this should go much higher
Based on past performance..... ENSC traded almost 4.5 million shares on 04/19/23 just on this NR: Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform
...more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on May 09, 2023 8:45am
ENSC..Great morning Folks...NR and volume/ sh price increase
Cheers !! Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection 2023-05-09 05:02 PT - News Release ~ Represents Major Milestone Towards Launch of
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 09, 2023 8:01am
New Press Release - Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
~ Represents Major Milestone Towards Launch of PF614-MPAR ~~ PF614-MPAR on Track to be the First Drug to Protect Against Overdose ~SAN DIEGO, CA / ACCESSWIRE / May 9, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), clinical-stage biotech company applying transformative chemistry to improve...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 19, 2023 2:13pm
ENSC...... Is that a lil gap down ?
Vols have dried up....share price is getting whack.... Mr. M is licking his chops and laughing all the way to the bank. Now he's sayin..... Anymore weak hands?
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth